Advanced search
Publication Cover
Pharmacogenomics Volume 13, 2012 - Issue 9
Submit an article Journal homepage
472
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Pathway-Based Pharmacogenomics of Gemcitabine Pharmacokinetics in Patients with Solid Tumors

Amit K Mitra1 Department of Experimental & Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USAView further author information
,
Mark N Kirstein1 Department of Experimental & Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA;2 PUMA-Institute of Personalized Medicine, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA;3 Masonic Comprehensive Cancer Center, University of Minnesota Minneapolis, MN, USAView further author information
,
Amit Khatri1 Department of Experimental & Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USAView further author information
,
Keith M Skubitz3 Masonic Comprehensive Cancer Center, University of Minnesota Minneapolis, MN, USA;4 Division of Hematology, Oncology & Transplantation, School of Medicine, University of Minnesota, Minneapolis, MN, USAView further author information
,
Arkadiusz Z Dudek3 Masonic Comprehensive Cancer Center, University of Minnesota Minneapolis, MN, USA;4 Division of Hematology, Oncology & Transplantation, School of Medicine, University of Minnesota, Minneapolis, MN, USAView further author information
,
Edward W Greeno3 Masonic Comprehensive Cancer Center, University of Minnesota Minneapolis, MN, USA;4 Division of Hematology, Oncology & Transplantation, School of Medicine, University of Minnesota, Minneapolis, MN, USAView further author information
,
Robert A Kratzke3 Masonic Comprehensive Cancer Center, University of Minnesota Minneapolis, MN, USA;4 Division of Hematology, Oncology & Transplantation, School of Medicine, University of Minnesota, Minneapolis, MN, USAView further author information
&
Jatinder K Lamba1 Department of Experimental & Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA;2 PUMA-Institute of Personalized Medicine, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA;3 Masonic Comprehensive Cancer Center, University of Minnesota Minneapolis, MN, USACorrespondence[email protected]
View further author information
 show all
Pages 1009-1021 | Published online: 27 Jul 2012

References

  • Dumontet C , MorschhauserF, Solal-CelignyP et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin‘s lymphoma. Br. J. Haematol. 113(3) , 772–778 (2001).
  • Metro G , CappuzzoF, FinocchiaroG, ToschiL, CrinoL. Development of gemcitabine in non-small cell lung cancer: the Italian contribution. Ann. Oncol.17(Suppl. 5) , V37–V46 (2006).
  • McDonagh EM , Whirl-CarrilloM, GartenY, AltmanRB, KleinTE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark. Med.5(6) , 795–806 (2011).
  • Mini E , NobiliS, CaciagliB, LandiniI, MazzeiT. Cellular pharmacology of gemcitabine. Ann. Oncol.17(Suppl. 5) , V7–V12 (2006).
  • Plunkett W , HuangP, XuYZ, HeinemannV, GrunewaldR, GandhiV. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol.22(4 Suppl. 11) , 3–10 (1995).
  • Rosell R , CoboM, IslaD, CampsC, MassutiB. Pharmacogenomics and gemcitabine. Ann. Oncol.17(Suppl. 5) , V13–V16 (2006).
  • Erculj N , KovacV, HmeljakJ, FrankoA, Dodic-FikfakM, DolzanV. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenet. Genomics22(1) , 58–68 (2012).
  • Wong AL , YapHL, YeoWL et al. Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients. Cancer Genomics Proteomics 8(5) , 255–259 (2011).
  • Kirstein MN , HassanI, GuireDE et al. High-performance liquid chromatographic method for the determination of gemcitabine and 2´,2´-difluorodeoxyuridine in plasma and tissue culture media. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 835(1–2) , 136–142 (2006).
  • Veltkamp SA , HillebrandMJ, RosingH et al. Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J. Mass Spectrom. 41(12) , 1633–1642 (2006).
  • Cheung RK , GrinsteinS, GelfandEW. Volume regulation by human lymphocytes. Identification of differences between the two major lymphocyte subpopulations. J. Clin. Invest.70(3) , 632–638 (1982).
  • Tham LS , WangL, SooRA et al. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin. Cancer Res. 14(13) , 4213–4218 (2008).
  • Mitra AK , CrewsKR, PoundsS et al. Genetic variants in cytosolic 5´-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J. Pharmacol. Exp. Ther. 339(1) , 9–23 (2011).
  • Li L , SchaidDJ, FridleyBL et al. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet. Genomics 22(2) , 105–116 (2012).
  • Ludovini V , FlorianiI, PistolaL et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J. Thorac. Oncol. 6(12) , 2018–2026 (2011).
  • Okazaki T , JavleM, TanakaM, AbbruzzeseJL, LiD. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin. Cancer Res.16(1) , 320–329 (2010).
  • Soo RA , WangLZ, NgSS et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 63(1) , 121–127 (2009).
  • Tibaldi C , GiovannettiE, TiseoM et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann. Oncol. 23(3) , 670–677 (2012).
  • Ryu JS , ShinES, NamHS et al. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. J. Thorac. Oncol. 6(8) , 1320–1329 (2011).
  • Gusella M , PasiniF, BolzonellaC et al. Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br. J. Clin. Pharmacol. 71(3) , 437–444 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.